Want to see BIOA full AI Analyst Report?
Top Page
BioAge Labs, Inc.
(NASDAQ:BIOA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.00
▼(-49.47% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by heavy ongoing losses and very large cash burn despite improving revenue, alongside a clearly bearish technical setup with the stock far below key moving averages. A strong, low-leverage balance sheet and generally stable corporate governance provide partial offset, but valuation remains constrained by negative earnings.
Positive Factors
Revenue Growth Trajectory
Consistent TTM revenue growth to $10.4M (~38% y/y) demonstrates early commercialization traction beyond preclinical activities. Durable top-line momentum helps de-risk the development profile, supports incremental investment in trials and commercial capabilities, and provides a foundation for future margin expansion.
Negative Factors
High Operating Cash Burn
Sustained operating outflows of roughly -$112M TTM indicate heavy cash consumption typical of clinical-stage biotech. This persistent burn will erode reserves absent financing or partnership, constraining strategic flexibility and raising the probability of capital raises that dilute existing shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Trajectory
Consistent TTM revenue growth to $10.4M (~38% y/y) demonstrates early commercialization traction beyond preclinical activities. Durable top-line momentum helps de-risk the development profile, supports incremental investment in trials and commercial capabilities, and provides a foundation for future margin expansion.
Read all positive factors
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$486.51M
Dividend YieldN/A
Average Volume (3M)668.29K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue Growth168.06%
EPS Growth-6.76%
CountryUS
Employees61
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.38
Shares Outstanding45,896,908
10 Day Avg. Volume554,284
30 Day Avg. Volume668,290
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.63Price Target Upside63.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.52
Revenue Forecast (FY)$7.60M
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insig...
How the Company Makes Money
null...
BioAge Labs, Inc. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.36M | 8.99M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.29M | 8.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -93.93M | -79.69M | -68.58M | -55.90M | -39.35M |
| Net Income | -94.46M | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | |||||
| Total Assets | 396.93M | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 318.75M | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 2.83M | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 22.02M | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 374.91M | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | |||||
| Free Cash Flow | -88.09M | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -87.60M | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -212.85M | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 154.15M | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Technical Analysis
Negative
21.77
Price Trends
19.21
Negative
18.21
Negative
16.76
Negative
Market Momentum
-3.03
Positive
31.67
Neutral
42.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOA, the sentiment is Negative. The current price of 21.77 is above the 20-day moving average (MA) of 15.95, above the 50-day MA of 19.21, and above the 200-day MA of 16.76, indicating a bearish trend. The MACD of -3.03 indicates Positive momentum. The RSI at 31.67 is Neutral, neither overbought nor oversold. The STOCH value of 42.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOA.
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAge Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $712.18M | 5.48 | -57.40% | ― | 26.19% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $189.67M | -28.60 | -20.23% | ― | 20.89% | 40.71% | |
47 Neutral | $486.51M | -4.37 | -28.99% | ― | 168.06% | -6.76% | |
46 Neutral | $178.67M | -4.13 | -250.83% | ― | ― | ― | |
45 Neutral | $39.24M | -1.48 | -92.47% | ― | -100.00% | 54.21% |
* General Sector Average
BIOA
BioAge Labs, Inc.
10.40
5.88
130.09%
IRWD
Ironwood Pharma
4.36
3.23
285.84%
LFCR
Lifecore Biomedical
4.54
-2.86
-38.65%
SXTC
China SXT Pharmaceuticals
3.75
-19,076.25
-99.98%
DERM
Journey Medical Corp
6.46
-0.54
-7.71%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.32
-8.68
-72.37%
BioAge Labs, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
Positive
Jun 12, 2026
On June 10, 2026, BioAge Labs, Inc. stockholders elected three Class II directors – Patrick Enright, M.B.A., James I. Healy, M.D., Ph.D., and Rekha Hemrajani, M.B.A. – to new three-year terms running through the 2029 annual meeting, so...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.